Cushing's Disease Clinical Trials

A listing of Cushing's Disease medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

 

Alabama

Birmingham Alabama 35294

A Phase 2 clinical study for patients with Cushing's Disease

Arizona

NEW

Advanced Research
Peoria Arizona 85381

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

California

NEW

UCLA School of Medicine
Los Angeles California 90095

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

Coastal Metabolic Research Center University Medical Center, Dept. of Endocrinology
Ventura California 93003

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Georgia

Atlanta Georgia 30322

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Illinois

Chicago Illinois 60611

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Maryland

Johns Hopkins University School of Medicine Division of Endocrinology, Diabetes & Metabolism
Baltimore Maryland 21287

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Massachusetts

Massachusetts General Hospital
Boston Massachusetts 02114

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Michigan

University of Michigan Medical Center Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin
Ann Arbor Michigan 48109

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Ann Arbor Michigan 48109-0944

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

New Mexico

University of New Mexico HSC
Albuquerque New Mexico 87131

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

New York

Icahn School of Medicine at Mount Sinai
New York New York 10029

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

New York New York 10032

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

New York New York 10029

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Ohio

Cleveland Clinic Endocrinology
Cleveland Ohio 44195

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

CarePoint East
Columbus Ohio 43203

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Oregon

Oregon Health & Science University
Portland Oregon

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Portland Oregon 97239

A Phase 2 clinical study for patients with Cushing's Disease

Pennsylvania

University of Pennslyvania Smilow Center for Translational Research
Philadelphia Pennsylvania 19104-5160

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

View More ▼

Philadelphia Pennsylvania 19104

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Rhode Island

NEW

Rhode Island Hospital, Hallett Center for Diabetes and Endocrinology
East Providence Rhode Island 02914

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Washington

NEW

Swedish Neuroscience Research
Seattle Washington 98122

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Wisconsin

Milwaukee Wisconsin 53226

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Belgium

NEW

Universitair Ziekenhuis
Brussel International 1090

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Canada

NEW

Centre hospitalier de l'Université de Montréal (CHUM)
Montreal International H2W 1T8

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

St. Paul's Hospital/Vancouver General Hospital
Vancouver International V6Z 1Y6

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Denmark

NEW

Aarhus University Hospital
Aarhus International 8000

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

Copenhagen University Hospital
Copenhagen International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

France

NEW

Attachée de Recherche Clinique Service d'Endocrinologie, Diabétologie, Maladies Métaboliques et Nutrition Hôpital du Haut-Lévêque
Pessac cedex International 33604

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Georgia

NEW

David Metreveli Medical Centre
Tbilisi International 0144

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Italy

NEW

Clinica di Endocrinologia e del Metabolismo
Ancona International 60126

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II
Naples International 80131

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

SCDU Medicina Interna I Università di Torino Dipartimento di Scienze Cliniche e Biologiche
Orbassano International 10043

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Netherlands

NEW

Leiden University, Leiden University Medical Center, Dept. of Endocrinology
Leiden International 2333 ZA

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

UK

NEW

Manchester Royal Infirmary
Manchester International M13 9WL

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

NEW

The Christie NHS Foundation Trust
Manchester International M20 4BX

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Belgium

UZLeuven Dienst endocrinologie
Leuven International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

France

Endocrinologie, Pavillon des Ecrins Centre Hospitalier Universitaire, Hopital Nord
Cedex International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Hôpital de la TIMONE Department of Endocrinology and Reference Center for Rare Pituitary Diseases
Marseille International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Centre de Réference Maladies Rares de la Surrénale, Service d'Endocrinologie, Hôpital Cochin
Paris International 75014

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Israel

Institute of Endocrinology & Metabolism Rabin Medical Center, Beilinson Campus
Petah Tiqva International 49100

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Netherlands

Erasmus MC, Dpt. Of Internal Medicine, Division of Endocrinology Centre Hospitalier Universitaire, Hopital Nord
Rotterdam International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Spain

Hospital Universitario de la Ribera Centre Hospitalier Universitaire, Hopital Nord
Alzira-Valencia International

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Hospital Sant Pau, Universitat Autònoma de Barcelona
Barcelona International 08025

An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Argentina

Caba Buenos Aires C1280AEB

A Phase 2 clinical study for patients with Cushing's Disease

Caba Buenos Aires C1180AAX

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Caba Buenos Aires C1426AAI

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Australia

Adelaide South Australia 5000

Patients are needed to participate in a clinical research study evaluating LCI699 for the treatment of Cushing's Disease

Darlinghurst New South Wales 2010

A Phase 2 clinical study for patients with Cushing's Disease

Woolloongabba Queensland 4102

A Phase 2 clinical study for patients with Cushing's Disease